Skip to main content

setanaxib

Generic: Setanaxib

setanaxib: 4 clinical trials tracked.

setanaxib evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about setanaxib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (4)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome

NCT06274489Registry updated 2026-04-13·Phase 1/Phase 2·CALT
Completed

Primary endpoint: Percentage of Patients With Serious Adverse Events (SAEs)

InterventionalRandomizedtriple20 enrolledStarted 2023-11Completion 2025-0617 sites · Austria, Czechia, France, Spain…Calliditas Therapeutics AB

A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN

NCT05323656Registry updated 2025-09-02·Phase 2
Completed

Primary endpoint: Best Percentage Change in Tumour Size

InterventionalRandomizeddouble55 enrolledStarted 2022-04Completion 2025-0824 sites · France, Germany, Italy, Poland…Calliditas Therapeutics Suisse SA

TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

NCT05014672Registry updated 2025-04-24·Phase 2
Completed

Primary endpoint: Change in ALP at Week 24 Compared to Baseline

InterventionalRandomizeddouble76 enrolledStarted 2022-02Completion 2024-0750 sites · Australia, Austria, Belgium, Canada…Calliditas Therapeutics Suisse SA

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria

NCT02010242Registry updated 2025-02-28·Phase 2·CALT
Completed

Primary endpoint: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group

InterventionalRandomizedquadruple136 enrolledStarted 2013-10Completion 2015-0348 sites · Australia, Canada, Czechia, Germany…Calliditas Therapeutics AB